H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Apollomics today and set a price target of $18.00. The company’s shares closed last Friday at $5.09, close to its 52-week low of $3.71.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.2% and a 21.3% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Springworks Therapeutics, and Neoleukin Therapeutics.
Currently, the analyst consensus on Apollomics is a Moderate Buy with an average price target of $21.50, a 264.4% upside from current levels. In a report issued on May 25, EF Hutton also maintained a Buy rating on the stock with a $25.00 price target.
CME Group (CME)
In a report issued on June 2, Christopher Allen from Citi reiterated a Buy rating on CME Group, with a price target of $210.00. The company’s shares closed last Friday at $185.30.
According to TipRanks.com, Allen is a 4-star analyst with an average return of 8.9% and a 62.1% success rate. Allen covers the Financial sector, focusing on stocks such as Raymond James Financial, Interactive Brokers, and Robinhood Markets.
Currently, the analyst consensus on CME Group is a Moderate Buy with an average price target of $206.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLM: